TRICALS: creating a highway toward a cure
van Eijk, Ruben P A; Kliest, Tessa; McDermott, Christopher J; Roes, Kit C B; Van Damme, Philip; Chio, Adriano; Weber, Markus; Ingre, Caroline; Corcia, Philippe; Povedano, Mònica; Reviers, Evy; van Es, Michael A; Al-Chalabi, Ammar; Hardiman, Orla; van den Berg, Leonard H
(2020) Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, volume 21, issue 7-8, pp. 496 - 501
(Article)
Abstract
A change in our current approach toward drug development is required to improve the likelihood of finding effective treatment for patients with amyotrophic lateral sclerosis (ALS). The aim of the Treatment Research Initiative to Cure ALS (TRICALS) is to extend the collective effort with industry and consolidate drug development paths.
... read more
TRICALS has begun a series of meetings on how to best move the field forward collaboratively, thereby addressing five major topics in ALS clinical trials: (1) preclinical research, (2) biomarker development, (3) eligibility criteria, (4) efficacy endpoints and (5) innovative trial design. There is an appetite for ongoing discussions of these major topics in clinical trials between representatives from academia, patient advocacy groups, industry partners and funding bodies. Industry is open to fundamentally change drug development for ALS and shorten the time to effective therapy for patients by implementing promising innovations in biomarker development, trial design, and patient selection. There is however, a pressing need from all stakeholders for regulatory discussions and amendments of current guidelines to successfully adopt innovation in future clinical development lines.
show less
Download/Full Text
Keywords: Clinical trial design, biomarkers, guidelines, preclinical, Clinical Neurology, Neurology, Journal Article
ISSN: 2167-8421
Publisher: Informa Healthcare
Note: Funding Information: This study was funded by the Dutch ALS foundation, UK Motor Neurone Disease Association (MNDA), ALS Liga Belgium and through the EU Joint Program?Neurodegenerative Disease Research, JPND. CJM is supported by the NIHR Sheffield Biomedical Research Center (BRC). Publisher Copyright: © 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
(Peer reviewed)